Multiple Myeloma

Sikander Ailawadhi, MD, discusses the emergence of T-cell engagers in multiple myeloma.

Yi Lin, MD, PhD, discusses CAR T-cell therapy–related toxicities in multiple myeloma.

January 13, 2021 — The FDA has granted an orphan drug designation to the BCMA-targeted trispecific T-cell activating recombinant protein construct as treatment for patients with multiple myeloma.

Rafael Fonseca, MD, discusses the emergence of minimal residual disease in multiple myeloma.

Marc J. Braunstein, MD, PhD, discusses the role of daratumumab in multiple myeloma.

Shaji K. Kumar, MD, discusses sequencing selinexor-based combinations in relapsed/refractory multiple myeloma.

Marc J. Braunstein, MD, PhD, discusses management strategies in multiple myeloma.

Yi Lin, MD, PhD, discusses the emergence of CAR T-cell therapy in multiple myeloma.

In our exclusive interview, Dr. Braunstein and Dr. Richter discuss navigating treatment selection for patients with the newly diagnosed multiple myeloma and the evolving role of minimal residual disease testing.

Sikander Ailawadhi, MD, discusses the potential role of melflufen in multiple myeloma.

A community can be defined by any number of characteristics. In Lonial’s case, he has built a community of physicians who’ve come together to treat patients with multiple myeloma.

Sikander Ailawadhi, MD, discusses the integration of selinexor into the treatment landscape of relapsed/refractory multiple myeloma.

Yi Lin, MD, PhD, discusses the characteristics of patients who were included in the CRB-401 study examining the CAR T-cell product idecabtagene vicleucel in multiple myeloma.

Yi Lin, MD, PhD, discusses the promise of the CAR T-cell products ciltacabtagene autoleucel and idecabtagene vicleucel in patients with myeloma.

December 21, 2020 - A rolling submission of the biologics license application for the BCMA-directed CAR T-cell product ciltacabtagene autoleucel for use in adults with relapsed/refractory multiple myeloma has been initiated to the FDA.

December 21, 2020 - The National Comprehensive Cancer Network has added 3 selinexor combination regimens to its Clinical Practice Guidelines in Oncology for previously treated patients with multiple myeloma.

December 18, 2020 - The FDA has approved selinexor in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least 1 previous therapy.